VI Partners

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.

Skribble is a platform for electronic signatures that presupposes the identification of the signatures. The platform provides the legally suitable electronic signature for every type of contract even if the law requires the same legal weight as a handwritten signature. It allows signing documents electronically with just a few clicks legally binding in accordance with Swiss & EU law. Skribble was founded in 2018 and is headquartered in Zurich, Switzerland.

Picterra SA is a company that operates an online platform designed to create and automate artificial intelligence (AI) workflows for object detection in geospatial data. Founded in 2016 and headquartered in Écublens, Switzerland, Picterra combines AI with satellite, drone, and aerial imagery to provide optimized geo-information. This platform enables users to monitor and anticipate changes in their environments, delivering valuable insights across various industries, including aerial imaging, mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, and the public sector. By leveraging cloud-based machine learning capabilities, Picterra empowers clients to efficiently extract and analyze earth observation data, facilitating informed decision-making.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Smart Valor AG is a blockchain-based fintech company based in Zug, Switzerland, established in 2017. It provides a comprehensive digital asset platform that facilitates the issuance and distribution of investment solutions and banking services. The company operates a digital asset exchange and offers asset management services, making it the first full-service digital asset provider in Switzerland and Liechtenstein. Smart Valor connects banks and fintechs to a decentralized network of investors, enabling access to tokenized and liquid investments across various asset classes, including real estate, currencies, and art. Additionally, it offers a white-label software-as-a-service solution that supports financial institutions with tools for compliance, performance tracking, and customer verification. The company has received recognition for its innovative approach, including an award from the Swiss governmental innovation agency Innosuisse.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Ledgy is a Swiss company founded in 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig, specializing in a platform for managing equity capital and employee participation. The platform offers a streamlined approach to overseeing vesting plans, phantom programs, and numbered shares, enhancing transparency in the equity management process. By digitizing these elements, Ledgy provides entrepreneurs and shareholders with valuable insights into their capital tables, funding rounds, and exit negotiations, facilitating better decision-making and clarity for all stakeholders involved.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

PicoDRILL SA is a private company based in Lausanne, Switzerland, specializing in micromachining techniques for creating hole structures in glass and dielectric materials. The company has developed a proprietary process known as Electrothermal Self-focusing, which enables the controlled heating and evaporation of precisely defined volumes in various substrates, including glass, ceramics, silica, and sapphire. This innovative technology addresses drilling needs within the nanotechnology sector, providing advanced solutions for its partners and customers.

Advanon AG is an online financial services platform based in Zurich, Switzerland, focused on connecting small and medium-sized enterprises (SMEs) with investors. Established in 2015, the platform specializes in invoice financing, allowing SMEs to pre-finance their outstanding invoices. This service enables businesses to access liquidity more quickly, avoiding the lengthy wait times of 30 to 120 days for customer payments. Advanon operates as an authorized financial intermediary under Swiss regulations, ensuring compliance with the Anti Money Laundering Act. By facilitating flexible financing options with transparent pricing, Advanon aims to support the growth and cash flow stability of SMEs.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Equippo.com is a commercial equipment company that sells and buys used equipment for the construction industry. They bring together select manufacturers, dealers, leasing companies, and other trusted sellers of heavy equipment with buyers from all over the world, including markets like South America, Russia, and Poland. It operates an online marketplace for used construction equipment. They are very proud of their most important and unique technological innovation - the Equippo final price calculation engine makes it even easier to deal internationally: tariffs, transport, and logistics specific to your region are already included in the price displayed. Equippo.com was founded in 2014 and is headquartered in Zug, Switzerland, Equippo’s dedicated team is as international as its mission; buyers and sellers can speak with salespeople in more than nine languages.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

L.E.S.S. SA, founded in 2012 and based in Renens, Switzerland, specializes in the design and development of ultra-bright and ultra-thin lighting solutions. The company offers a range of products, including inspection lighting for microscopy and workbench applications, as well as automotive lighting systems. L.E.S.S. focuses on providing high and low angle, and shadowless illumination lighting systems suitable for various sectors, including automotive, machine vision, watchmaking, micromechanics, electronics, and medical applications. The company's innovative approach aims to deliver intense and uniform lighting within a compact form factor.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Sonic Emotion AG is a Swiss company specializing in innovative audio solutions that deliver immersive 3D sound experiences. Founded in 2002 and headquartered in Zurich, with research facilities in France and sales offices across Asia, Sonic Emotion offers advanced audio technologies suitable for various environments, including 3D cinemas, events, museums, and theme parks. The company's flagship product, Absolute 3D sound technology, enables natural sound reproduction using a compact system that can operate with minimal channels, making it versatile for different applications. Additionally, Sonic Emotion provides audio simulation and OEM licensing solutions, as well as Headquake, a sound enhancement application for Apple devices. The company's focus on creating engaging audio experiences positions it as a leader in the field of sound technology.

windeln.de, together with its subsidiaries, operates as an online retailer of products for babies, toddlers, children, and young mothers in Germany, Austria, Switzerland, the Czech Republic, Spain, and China. It operates through German Shop, International Shops, and Shopping Clubs segments. The company offers a range of products, including diapers, baby food, drugstore products, clothes, toys, strollers, child car seats, baby monitors, and children’s furniture.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne. The company focuses on developing innovative therapeutic peptides aimed at treating inflammation. Xigen's peptides offer metabolic stability and specificity, allowing for selective delivery to intracellular targets through proprietary carrier molecules. This technology enables healthcare professionals to address a wide range of diseases effectively. The company is led by Dr. Christophe Bonny, a molecular biologist with extensive research experience in intracellular peptides and signaling.

Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.